Abstract
Infliximab, a chimeric human-mouse anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, can inhibit the binding of TNF-alpha with its soluble and membrane receptor and inactivate TNF-alpha. Clinically, it has been used to treat TNF-alpha-associated diseases. However, it may cause the development of infection, psoriasis, lupus erythematosus, atopic dermatitis and skin neoplasms during the treatment of ankylosing spondylitis, rheumatoid arthritis and other diseases. This article describes skin manifestations related to treatment with infliximab so as to remind clinicians to pay attention to the association between skin diseases and infliximab. Key words: Skin diseases; Infliximab; Tumor necrosis factor-alpha
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
